Merck's affordable Ebola vaccine initiatives, Abbott's profit challenges, U.S. vaccination policy changes under Health ...

While the pandemic caused some of Abbott's segments to balloon (diagnostics) and others to fall short (medical devices), conditions have largely normalized and Abbott's prospects will again rely ...

Abbott Labs stock drops on sales miss and weak guidance for 2026, analyst cuts price target but maintains rating.

Snacks are increasingly replacing meals as eating patterns shift. Hartman Group data presented at FoodNavigator's Healthy ...

Abbott shares sank 8% as Q4 revenue of $11.5B missed the $11.8B target, with nutrition sales dropping 8.9% on price ...

Abbott Laboratories reported Q4 2025 sales of $11.46 billion, an increase of 4.4% from the previous year but falling short of analyst projections by approximately 3%. The adjusted EPS was $1.50, ...

Abbott Laboratories (NYSE:ABT) Q4 2025 Earnings Call Transcript January 22, 2026 Abbott Laboratories reports earnings inline ...

Abbott Laboratories saw its shares down 10% at the end of trading Thursday, Jan. 22, as the market digested weaknesses from its fourth-quarter and full-year earnings report. | Abbott Laboratories saw ...

Abbott Laboratories fell on its latest earnings report, but I view this as a buying opportunity. Read the latest analysis on ...

Abbott Laboratories reported fourth quarter sales below expectations before the market opened on Jan. 22, sending the stock down nearly 12% from the prior day's closing. The biggest hits came from ...

The mixed earnings report comes on the heels of the Abbott Park, IL-based company announcing it would acquire Exact Sciences for $21 billion.

Looking ahead, Abbott forecast organic sales growth in the range of 6.5% to 7.5%, the midpoint of which missed Wall Street ...